Cellectis reports Q4 EPS (59c), consensus (71c)

Reports Q4 revenue $25.7M, consensus $13.92M. As of December 31, 2022, Cellectis, excluding Calyxt, had $95M in consolidated cash, cash equivalents, and restricted cash vs. $177M as of December 31, 2021. "In 2022, Cellectis presented positive preliminary clinical data from five additional patients from its BALLI-01 trial evaluating UCART22 in patients with r/r B-cell ALL. The results showed evidence of UCART22 anti-tumor activity observed in three of the first five patients (60%) that were treated at DL3. Overall, these preliminary data support the continued administration of UCART22 after FCA lymphodepletion in patients with r/r B-cell ALL. We are excited by these preliminary clinical responses for the patients who have limited, if any, treatment options, especially for those who have failed prior CD19 directed CAR T-cell therapy and allogeneic stem cell transplant. UCART22 is currently the most advanced allogeneic CAR T-cell product in development for ALL.." said CEO Andre Choulika….This year, Cellectis remains deeply focused on the patient recruitment of its four ongoing Phase 1 clinical trials BALLI-01, AMELI-01, MELANI-01 and NATHALI-01 evaluating UCART22, UCART123, UCARTCS1 and UCART20x22 respectively".